In this webinar, we explore two scenarios that can open Medical Affairs up to censure. Scenario one explores participation of commercial team members in Medical Advisory Boards and scenario two looks at the implications of a commercial team member requesting a medical team member to participate in a thought leader meeting.
Who is a Digital Opinion Leader? How to engage a DOL? Harmonize understanding of who a DOL is and the milestones to be considered in the implementation of a DOL initiative; build a well-defined road map to implement a DOL engagement initiative at a local level
Real world data (RWD), when captured and analyzed, produces the Real-World Evidence (RWE) that underpins the economic case for innovative medicines. This Webinar aims to provide practical insight into the challenges surrounding RWD and RWE generation with interactive conversation on how individual companies are approaching these challenges.
Explore the pitfalls of career transitions, and how to overcome them; look at the key foundations required to make a successful career transition; hear real-life stories, and learn actionable tips, from others who have navigated complex career transitions; explore why health & wellbeing should be a priority on your transition agenda
Examine the current state & future of HEOR data in healthcare decision-making; discuss strategies to build strong relationships with payers, the medical community, and patient advocacy groups; determine the impact and value of evidence-based pricing and payment
This Webinar will discuss the process of investigator initiated research program followed across industry. The process is initiated externally by submission of IIR application via company website followed by internal company review and decision making process. This results in the execution of IIR study contract between the company and the Institution after which the study is initiated by the Investigator.
This Webinar discusses current trends and anticipated innovations, including the use of outcomes-based agreements; why traditional contracting may not be enough to address the needs of both payers and pharma manufacturers; and insights on the key payer engagement issues you should be considering today to optimize the market success of your products.
Analysis of RWD leads to clinical evidence known as real world evidence (RWE) regarding the usage and risks and benefits of a therapy. Under the right conditions, RWD and the RWE that follows may be used to support regulatory decisions and contribute to the knowledge of a drug or therapy. RWE may help to support improved decision-making about health and health care.